Research Summary
Biopharmaceuticals are medical drugs produced using living organisms or biological systems, as opposed to traditional chemically synthesized pharmaceuticals. These drugs include a wide range of products such as monoclonal antibodies, vaccines, recombinant proteins, and gene therapies, which are used to treat various diseases, including cancer, autoimmune disorders, and infectious diseases. Biopharmaceuticals often require complex manufacturing processes involving cell cultures or fermentation. A Bio-CDMO (Biopharmaceutical Contract Development and Manufacturing Organization) is a specialized service provider that assists biopharmaceutical companies in developing and manufacturing these complex biologic drugs. Bio-CDMOs offer a range of services, including process development, scale-up, clinical and commercial production, and regulatory support, helping clients bring biopharmaceutical products to market more efficiently and cost-effectively. These organizations provide expertise in areas such as biologic formulation, purification, and quality control, ensuring that biopharmaceuticals are produced at high quality and in compliance with regulatory standards, often for clients who lack the resources or facilities to handle production in-house.
According to WENKH research statistics, the global Biopharmaceutical and Bio-CDMO market size will reach 34,933 Million USD in 2025 and is projected to reach 85,499 Million USD by 2032, with a CAGR of 13.64% (2025-2032). Among them, the Asia-Pacific Biopharmaceutical and Bio-CDMO market is undergoing rapid changes, reaching Million USD in 2025, accounting for approximately % of the global market share. It is projected to reach Million USD by 2032.
The global Biopharmaceutical and Bio-CDMO market is highly competitive, with key market players including Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, WuXi Biologics, Recipharm, Thermo Fisher Scientific, AGC Biologics, Rentschler Biopharma, KBI Biopharma, Siegfried, Aenova Group, GenScript, ProBioGen, Northway Biotech, 3P Biopharmaceuticals, etc. This report categorizes the competitive landscape of the global Biopharmaceutical and Bio-CDMO market into three tiers based on annual revenue, with the top three market players holding approximately % of the total market share.
This report provides an in-depth analysis of the global Biopharmaceutical and Bio-CDMO market, including market size, price trends, market status and future development prospects. It particularly focuses on the market share, product characteristics, pricing, sales revenue, and gross profit margin of major players in the global Biopharmaceutical and Bio-CDMO industry. Additionally, this report provides an in-depth analysis of the market status and future development trends of different product segments of Biopharmaceutical and Bio-CDMO and their downstream application fields.
In terms of data, this report includes a comprehensive time-series dataset. The historical data spans from 2020 to 2024, providing a solid foundation for analyzing past market trends. The year 2025 is used as a base year to accurately assess the current market landscape. Forecast data covers the period from 2026 to 2032, utilizing scientific analysis methods and models to offer forward-looking predictions and insights into the market's future development. This provides valuable reference information for industry participants and stakeholders.
The report covers countries including United States, China, Germany, Japan, France, South Korea, United Kingdom, India, Italy, Brazil, Mexico, Indonesia, Vietnam and South Africa. It particularly focuses on the sales revenue of Biopharmaceutical and Bio-CDMO in these countries, as well as the product segmentation and downstream application market size of each country. The report provides an in-depth analysis of the regional distribution and future development trends of the Biopharmaceutical and Bio-CDMO market. By considering local policies, this report evaluates the market prospects of Biopharmaceutical and Bio-CDMO in each country, aiming to help companies gain a comprehensive understanding of the industry characteristics and development potential in different regions, optimize regional business layout, and develop precise market strategies to achieve global development goals.
This report places a strong emphasis on data quality and reliability, utilizing diverse and extensive data sources to ensure the accuracy and validity of the information presented. Primary data collection involves multiple channels, including in-depth interviews with senior executives, industry experts, supply chain stakeholders, and end consumers. These interviews provide key insights into corporate strategic planning, industry policy interpretation, supply chain dynamics, and end-user experiences. Secondary data sources cover a wide range of authoritative statistics from government agencies, customs databases, industry associations, third-party paid databases, brokerage research reports, academic research findings, corporate annual reports, financial statements, real-time news updates, and relevant information from international organizations. These data sources serve as a solid foundation for verification and analysis.
Companies Covered
Lonza
Catalent
Samsung Biologics
FUJIFILM Diosynth Biotechnologies
Boehringer Ingelheim
WuXi Biologics
Recipharm
Thermo Fisher Scientific
AGC Biologics
Rentschler Biopharma
KBI Biopharma
Siegfried
Aenova Group
GenScript
ProBioGen
Northway Biotech
3P Biopharmaceuticals
Product Segment
Cell and Gene Therapies
Antibodies
Vaccines
Others
Product Application
SMBs
Large Companies
Chapter Scope
Chapter 1: Product Statistical Scope, Product Segmentation Types and Downstream Applications, Overall Market Size, Current Status and Development Prospects
Chapter 2: Global Biopharmaceutical and Bio-CDMO Industry Chain Analysis
Chapter 3: Global Biopharmaceutical and Bio-CDMO Industry Environment Analysis and Porter's Five Forces Analysis
Chapter 4: Analysis of the Competitive Landscape of Major Companies in the Global Biopharmaceutical and Bio-CDMO Market (Market Share, Product Revenue Comparison, Tier Division, Corporate Expansion and M&A Trends)
Chapter 5: Analysis of Global Major Companies (Company Profiles, Product Specifications and Features, Product Revenue and Product Gross Profit Margin)
Chapter 6: Global Biopharmaceutical and Bio-CDMO Market Analysis by Countries, Product Segment and Downstream Application
Chapter 7: United States Biopharmaceutical and Bio-CDMO Market Size, Product Segment, Downstream Application Analysis
Chapter 8: China Biopharmaceutical and Bio-CDMO Market Size, Product Segment, Downstream Application Analysis
Chapter 9: Germany Biopharmaceutical and Bio-CDMO Market Size, Product Segment, Downstream Application Analysis
Chapter 10: Japan Biopharmaceutical and Bio-CDMO Market Size, Product Segment, Downstream Application Analysis
Chapter 11: France Biopharmaceutical and Bio-CDMO Market Size, Product Segment, Downstream Application Analysis
Chapter 12: South Korea Biopharmaceutical and Bio-CDMO Market Size, Product Segment, Downstream Application Analysis
Chapter 13: United Kingdom Biopharmaceutical and Bio-CDMO Market Size, Product Segment, Downstream Application Analysis
Chapter 14: India Biopharmaceutical and Bio-CDMO Market Size, Product Segment, Downstream Application Analysis
Chapter 15: Italy Biopharmaceutical and Bio-CDMO Market Size, Product Segment, Downstream Application Analysis
Chapter 16: Brazil Biopharmaceutical and Bio-CDMO Market Size, Product Segment, Downstream Application Analysis
Chapter 17: Mexico Biopharmaceutical and Bio-CDMO Market Size, Product Segment, Downstream Application Analysis
Chapter 18: Indonesia Biopharmaceutical and Bio-CDMO Market Size, Product Segment, Downstream Application Analysis
Chapter 19: Vietnam Biopharmaceutical and Bio-CDMO Market Size, Product Segment, Downstream Application Analysis
Chapter 20: South Africa Biopharmaceutical and Bio-CDMO Market Size, Product Segment, Downstream Application Analysis
Chapter 21: Research Conclusion
Chapter 22: Methodology and Data Source
Purpose and Value of the Report
Market Trend Insights: Analyze industry trends, market dynamics, and future growth potential to help companies forecast changes and develop strategic plans.
Competitive Landscape Analysis: Understand key players' revenue segmentation, strategies, market share, and business models to guide competitive decisions.
Investment Decision Support: Provide feasibility analysis through market size, growth rate, demand trends, and potential risks for informed investment decisions.
Target Customer and Demand Analysis: Examine consumer behavior, purchasing preferences, and pain points to optimize products and improve market penetration.
Policy and Regulatory Insights: Interpret relevant industry policies to ensure compliance and mitigate regulatory risks.
Business Model Optimization: Offer data-driven suggestions for enhancing business models and improving profitability.
Table of Content
1 Biopharmaceutical and Bio-CDMO Market Overview
1.1 Product Definition Introduction
1.2 Global Biopharmaceutical and Bio-CDMO Market Size and Growth Forecast Analysis (2020-2032)
1.3 Biopharmaceutical and Bio-CDMO Market Status and Development Prospects
1.3.1 Biopharmaceutical and Bio-CDMO Market Status
1.3.2 Biopharmaceutical and Bio-CDMO Industry Development Prospects
1.4 Biopharmaceutical and Bio-CDMO Market Overview by Product Segment
1.4.1 Global Biopharmaceutical and Bio-CDMO Market Size and Growth Forecast Analysis by Product Segment: 2020 VS 2025 VS 2032
1.4.2 Cell and Gene Therapies
1.4.3 Antibodies
1.4.4 Vaccines
1.4.5 Others
1.5 Biopharmaceutical and Bio-CDMO Market Overview by Product Application
1.5.1 Global Biopharmaceutical and Bio-CDMO Market Size and Growth Forecast Analysis by Product Application: 2020 VS 2025 VS 2032
1.5.2 SMBs
1.5.3 Large Companies
2 Biopharmaceutical and Bio-CDMO Industry Supply Chain Analysis
2.1 Biopharmaceutical and Bio-CDMO Supply Chain
2.2 Biopharmaceutical and Bio-CDMO Midstream Suppliers
2.3 Biopharmaceutical and Bio-CDMO Downstream Customers
2.4 Biopharmaceutical and Bio-CDMO Sales Channel Analysis
3 Biopharmaceutical and Bio-CDMO Market Environment Analysis
3.1 Biopharmaceutical and Bio-CDMO Industry Policy Analysis
3.2 Biopharmaceutical and Bio-CDMO Emerging Technology Trends in the Industry
3.3 Biopharmaceutical and Bio-CDMO Restraining Factors Analysis
3.4 Biopharmaceutical and Bio-CDMO Market Porter's Five Forces Analysis
3.4.1 Competitive Rivalry
3.4.2 Threat of New Entrants
3.4.3 Bargaining Power of Suppliers
3.4.4 Bargaining Power of Buyers
3.4.5 Threat of Substitute Products or Services
4 Global Biopharmaceutical and Bio-CDMO Market Players Competition Landscape
4.1 Global Biopharmaceutical and Bio-CDMO Market Revenue by Key Players (2021-2025)
4.2 Global Biopharmaceutical and Bio-CDMO Market Position by Key Players
4.3 Global Key Players Headquarter and Key Area Served
4.4 Global Biopharmaceutical and Bio-CDMO Market Expansion and M&A Dynamic
5 In-depth Analysis of Key Players
5.1 Lonza
5.1.1 Lonza Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.1.2 Lonza Biopharmaceutical and Bio-CDMO Product Features
5.1.3 Lonza Biopharmaceutical and Bio-CDMO Product Revenue and Gross Margin Analysis (2021-2025)
5.2 Catalent
5.2.1 Catalent Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.2.2 Catalent Biopharmaceutical and Bio-CDMO Product Features
5.2.3 Catalent Biopharmaceutical and Bio-CDMO Product Revenue and Gross Margin Analysis (2021-2025)
5.3 Samsung Biologics
5.3.1 Samsung Biologics Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.3.2 Samsung Biologics Biopharmaceutical and Bio-CDMO Product Features
5.3.3 Samsung Biologics Biopharmaceutical and Bio-CDMO Product Revenue and Gross Margin Analysis (2021-2025)
5.4 FUJIFILM Diosynth Biotechnologies
5.4.1 FUJIFILM Diosynth Biotechnologies Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.4.2 FUJIFILM Diosynth Biotechnologies Biopharmaceutical and Bio-CDMO Product Features
5.4.3 FUJIFILM Diosynth Biotechnologies Biopharmaceutical and Bio-CDMO Product Revenue and Gross Margin Analysis (2021-2025)
5.5 Boehringer Ingelheim
5.5.1 Boehringer Ingelheim Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.5.2 Boehringer Ingelheim Biopharmaceutical and Bio-CDMO Product Features
5.5.3 Boehringer Ingelheim Biopharmaceutical and Bio-CDMO Product Revenue and Gross Margin Analysis (2021-2025)
5.6 WuXi Biologics
5.6.1 WuXi Biologics Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.6.2 WuXi Biologics Biopharmaceutical and Bio-CDMO Product Features
5.6.3 WuXi Biologics Biopharmaceutical and Bio-CDMO Product Revenue and Gross Margin Analysis (2021-2025)
5.7 Recipharm
5.7.1 Recipharm Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.7.2 Recipharm Biopharmaceutical and Bio-CDMO Product Features
5.7.3 Recipharm Biopharmaceutical and Bio-CDMO Product Revenue and Gross Margin Analysis (2021-2025)
5.8 Thermo Fisher Scientific
5.8.1 Thermo Fisher Scientific Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.8.2 Thermo Fisher Scientific Biopharmaceutical and Bio-CDMO Product Features
5.8.3 Thermo Fisher Scientific Biopharmaceutical and Bio-CDMO Product Revenue and Gross Margin Analysis (2021-2025)
5.9 AGC Biologics
5.9.1 AGC Biologics Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.9.2 AGC Biologics Biopharmaceutical and Bio-CDMO Product Features
5.9.3 AGC Biologics Biopharmaceutical and Bio-CDMO Product Revenue and Gross Margin Analysis (2021-2025)
5.10 Rentschler Biopharma
5.10.1 Rentschler Biopharma Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.10.2 Rentschler Biopharma Biopharmaceutical and Bio-CDMO Product Features
5.10.3 Rentschler Biopharma Biopharmaceutical and Bio-CDMO Product Revenue and Gross Margin Analysis (2021-2025)
5.11 KBI Biopharma
5.11.1 KBI Biopharma Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.11.2 KBI Biopharma Biopharmaceutical and Bio-CDMO Product Features
5.11.3 KBI Biopharma Biopharmaceutical and Bio-CDMO Product Revenue and Gross Margin Analysis (2021-2025)
5.12 Siegfried
5.12.1 Siegfried Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.12.2 Siegfried Biopharmaceutical and Bio-CDMO Product Features
5.12.3 Siegfried Biopharmaceutical and Bio-CDMO Product Revenue and Gross Margin Analysis (2021-2025)
5.13 Aenova Group
5.13.1 Aenova Group Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.13.2 Aenova Group Biopharmaceutical and Bio-CDMO Product Features
5.13.3 Aenova Group Biopharmaceutical and Bio-CDMO Product Revenue and Gross Margin Analysis (2021-2025)
5.14 GenScript
5.14.1 GenScript Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.14.2 GenScript Biopharmaceutical and Bio-CDMO Product Features
5.14.3 GenScript Biopharmaceutical and Bio-CDMO Product Revenue and Gross Margin Analysis (2021-2025)
5.15 ProBioGen
5.15.1 ProBioGen Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.15.2 ProBioGen Biopharmaceutical and Bio-CDMO Product Features
5.15.3 ProBioGen Biopharmaceutical and Bio-CDMO Product Revenue and Gross Margin Analysis (2021-2025)
5.16 Northway Biotech
5.16.1 Northway Biotech Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.16.2 Northway Biotech Biopharmaceutical and Bio-CDMO Product Features
5.16.3 Northway Biotech Biopharmaceutical and Bio-CDMO Product Revenue and Gross Margin Analysis (2021-2025)
5.17 3P Biopharmaceuticals
5.17.1 3P Biopharmaceuticals Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
5.17.2 3P Biopharmaceuticals Biopharmaceutical and Bio-CDMO Product Features
5.17.3 3P Biopharmaceuticals Biopharmaceutical and Bio-CDMO Product Revenue and Gross Margin Analysis (2021-2025)
6 Global Biopharmaceutical and Bio-CDMO Market Analysis by Countries, by Product Segment and Application
6.1 Global Biopharmaceutical and Bio-CDMO Market Size and Growth Forecast by Countries: 2020 VS 2025 VS 2032
6.1.1 Global Biopharmaceutical and Bio-CDMO Market Revenue by Countries (2020-2025)
6.1.2 Global Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Countries (2026-2032)
6.2 Global Biopharmaceutical and Bio-CDMO Market Size by Product Segment (2020-2032)
6.3 Global Biopharmaceutical and Bio-CDMO Market Size by Product Application (2020-2032)
7 United States Biopharmaceutical and Bio-CDMO Market Analysis
7.1 United States Biopharmaceutical and Bio-CDMO Market Prospects
7.2 United States Biopharmaceutical and Bio-CDMO Market Size by Product Segment (2020-2032)
7.3 United States Biopharmaceutical and Bio-CDMO Market Size by Product Application (2020-2032)
8 China Biopharmaceutical and Bio-CDMO Market Analysis
8.1 China Biopharmaceutical and Bio-CDMO Market Prospects
8.2 China Biopharmaceutical and Bio-CDMO Market Size by Product Segment (2020-2032)
8.3 China Biopharmaceutical and Bio-CDMO Market Size by Product Application (2020-2032)
9 Germany Biopharmaceutical and Bio-CDMO Market Analysis
9.1 Germany Biopharmaceutical and Bio-CDMO Market Prospects
9.2 Germany Biopharmaceutical and Bio-CDMO Market Size by Product Segment (2020-2032)
9.3 Germany Biopharmaceutical and Bio-CDMO Market Size by Product Application (2020-2032)
10 Japan Biopharmaceutical and Bio-CDMO Market Analysis
10.1 Japan Biopharmaceutical and Bio-CDMO Market Prospects
10.2 Japan Biopharmaceutical and Bio-CDMO Market Size by Product Segment (2020-2032)
10.3 Japan Biopharmaceutical and Bio-CDMO Market Size by Product Application (2020-2032)
11 France Biopharmaceutical and Bio-CDMO Market Analysis
11.1 France Biopharmaceutical and Bio-CDMO Market Prospects
11.2 France Biopharmaceutical and Bio-CDMO Market Size by Product Segment (2020-2032)
11.3 France Biopharmaceutical and Bio-CDMO Market Size by Product Application (2020-2032)
12 South Korea Biopharmaceutical and Bio-CDMO Market Analysis
12.1 South Korea Biopharmaceutical and Bio-CDMO Market Prospects
12.2 South Korea Biopharmaceutical and Bio-CDMO Market Size by Product Segment (2020-2032)
12.3 South Korea Biopharmaceutical and Bio-CDMO Market Size by Product Application (2020-2032)
13 United Kingdom Biopharmaceutical and Bio-CDMO Market Analysis
13.1 United Kingdom Biopharmaceutical and Bio-CDMO Market Prospects
13.2 United Kingdom Biopharmaceutical and Bio-CDMO Market Size by Product Segment (2020-2032)
13.3 United Kingdom Biopharmaceutical and Bio-CDMO Market Size by Product Application (2020-2032)
14 India Biopharmaceutical and Bio-CDMO Market Analysis
14.1 India Biopharmaceutical and Bio-CDMO Market Prospects
14.2 India Biopharmaceutical and Bio-CDMO Market Size by Product Segment (2020-2032)
14.3 India Biopharmaceutical and Bio-CDMO Market Size by Product Application (2020-2032)
15 Italy Biopharmaceutical and Bio-CDMO Market Analysis
15.1 Italy Biopharmaceutical and Bio-CDMO Market Prospects
15.2 Italy Biopharmaceutical and Bio-CDMO Market Size by Product Segment (2020-2032)
15.3 Italy Biopharmaceutical and Bio-CDMO Market Size by Product Application (2020-2032)
16 Brazil Biopharmaceutical and Bio-CDMO Market Analysis
16.1 Brazil Biopharmaceutical and Bio-CDMO Market Prospects
16.2 Brazil Biopharmaceutical and Bio-CDMO Market Size by Product Segment (2020-2032)
16.3 Brazil Biopharmaceutical and Bio-CDMO Market Size by Product Application (2020-2032)
17 Mexico Biopharmaceutical and Bio-CDMO Market Analysis
17.1 Mexico Biopharmaceutical and Bio-CDMO Market Prospects
17.2 Mexico Biopharmaceutical and Bio-CDMO Market Size by Product Segment (2020-2032)
17.3 Mexico Biopharmaceutical and Bio-CDMO Market Size by Product Application (2020-2032)
18 Indonesia Biopharmaceutical and Bio-CDMO Market Analysis
18.1 Indonesia Biopharmaceutical and Bio-CDMO Market Prospects
18.2 Indonesia Biopharmaceutical and Bio-CDMO Market Size by Product Segment (2020-2032)
18.3 Indonesia Biopharmaceutical and Bio-CDMO Market Size by Product Application (2020-2032)
19 Vietnam Biopharmaceutical and Bio-CDMO Market Analysis
19.1 Vietnam Biopharmaceutical and Bio-CDMO Market Prospects
19.2 Vietnam Biopharmaceutical and Bio-CDMO Market Size by Product Segment (2020-2032)
19.3 Vietnam Biopharmaceutical and Bio-CDMO Market Size by Product Application (2020-2032)
20 South Africa Biopharmaceutical and Bio-CDMO Market Analysis
20.1 South Africa Biopharmaceutical and Bio-CDMO Market Prospects
20.2 South Africa Biopharmaceutical and Bio-CDMO Market Size by Product Segment (2020-2032)
20.3 South Africa Biopharmaceutical and Bio-CDMO Market Size by Product Application (2020-2032)
21 Research Conclusion
22 Appendix
22.1 Methodology/Research Approach
22.2 Research Landscape
22.3 Research Benchmark and Hypothesis
22.4 Data Source
22.4.1 Primary Sources
22.4.2 Secondary Sources
22.5 Data Cross Validation
22.6 Disclaimer
Table 1：Global Biopharmaceutical and Bio-CDMO Market Size and Growth Forecast Analysis by Product Segment (2020 VS 2025 VS 2032) & (Million USD)
Table 2：Global Biopharmaceutical and Bio-CDMO Market Size and Growth Forecast Analysis by Product Application (2020 VS 2025 VS 2032) & (Million USD)
Table 3：Biopharmaceutical and Bio-CDMO Downstream Customers List
Table 4：Biopharmaceutical and Bio-CDMO Distributors/Dealers List
Table 5：Global Biopharmaceutical and Bio-CDMO Market Revenue by Key Players (2021-2025) & (Million USD)
Table 6：Global Biopharmaceutical and Bio-CDMO Market Position by Key Players
Table 7：Global Key Players Headquarter and Key Area Served
Table 8：Global Biopharmaceutical and Bio-CDMO Market Expansion and M&A Dynamic
Table 9：Lonza Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 10：Lonza Biopharmaceutical and Bio-CDMO Product Features
Table 11：Lonza Biopharmaceutical and Bio-CDMO Revenue (Million USD) and Gross Margin (2021-2025)
Table 12：Catalent Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 13：Catalent Biopharmaceutical and Bio-CDMO Product Features
Table 14：Catalent Biopharmaceutical and Bio-CDMO Revenue (Million USD) and Gross Margin (2021-2025)
Table 15：Samsung Biologics Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 16：Samsung Biologics Biopharmaceutical and Bio-CDMO Product Features
Table 17：Samsung Biologics Biopharmaceutical and Bio-CDMO Revenue (Million USD) and Gross Margin (2021-2025)
Table 18：FUJIFILM Diosynth Biotechnologies Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 19：FUJIFILM Diosynth Biotechnologies Biopharmaceutical and Bio-CDMO Product Features
Table 20：FUJIFILM Diosynth Biotechnologies Biopharmaceutical and Bio-CDMO Revenue (Million USD) and Gross Margin (2021-2025)
Table 21：Boehringer Ingelheim Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 22：Boehringer Ingelheim Biopharmaceutical and Bio-CDMO Product Features
Table 23：Boehringer Ingelheim Biopharmaceutical and Bio-CDMO Revenue (Million USD) and Gross Margin (2021-2025)
Table 24：WuXi Biologics Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 25：WuXi Biologics Biopharmaceutical and Bio-CDMO Product Features
Table 26：WuXi Biologics Biopharmaceutical and Bio-CDMO Revenue (Million USD) and Gross Margin (2021-2025)
Table 27：Recipharm Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 28：Recipharm Biopharmaceutical and Bio-CDMO Product Features
Table 29：Recipharm Biopharmaceutical and Bio-CDMO Revenue (Million USD) and Gross Margin (2021-2025)
Table 30：Thermo Fisher Scientific Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 31：Thermo Fisher Scientific Biopharmaceutical and Bio-CDMO Product Features
Table 32：Thermo Fisher Scientific Biopharmaceutical and Bio-CDMO Revenue (Million USD) and Gross Margin (2021-2025)
Table 33：AGC Biologics Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 34：AGC Biologics Biopharmaceutical and Bio-CDMO Product Features
Table 35：AGC Biologics Biopharmaceutical and Bio-CDMO Revenue (Million USD) and Gross Margin (2021-2025)
Table 36：Rentschler Biopharma Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 37：Rentschler Biopharma Biopharmaceutical and Bio-CDMO Product Features
Table 38：Rentschler Biopharma Biopharmaceutical and Bio-CDMO Revenue (Million USD) and Gross Margin (2021-2025)
Table 39：KBI Biopharma Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 40：KBI Biopharma Biopharmaceutical and Bio-CDMO Product Features
Table 41：KBI Biopharma Biopharmaceutical and Bio-CDMO Revenue (Million USD) and Gross Margin (2021-2025)
Table 42：Siegfried Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 43：Siegfried Biopharmaceutical and Bio-CDMO Product Features
Table 44：Siegfried Biopharmaceutical and Bio-CDMO Revenue (Million USD) and Gross Margin (2021-2025)
Table 45：Aenova Group Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 46：Aenova Group Biopharmaceutical and Bio-CDMO Product Features
Table 47：Aenova Group Biopharmaceutical and Bio-CDMO Revenue (Million USD) and Gross Margin (2021-2025)
Table 48：GenScript Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 49：GenScript Biopharmaceutical and Bio-CDMO Product Features
Table 50：GenScript Biopharmaceutical and Bio-CDMO Revenue (Million USD) and Gross Margin (2021-2025)
Table 51：ProBioGen Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 52：ProBioGen Biopharmaceutical and Bio-CDMO Product Features
Table 53：ProBioGen Biopharmaceutical and Bio-CDMO Revenue (Million USD) and Gross Margin (2021-2025)
Table 54：Northway Biotech Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 55：Northway Biotech Biopharmaceutical and Bio-CDMO Product Features
Table 56：Northway Biotech Biopharmaceutical and Bio-CDMO Revenue (Million USD) and Gross Margin (2021-2025)
Table 57：3P Biopharmaceuticals Basic Information (Total Revenue, Employees, Main Business, Service Area and Contact Information)
Table 58：3P Biopharmaceuticals Biopharmaceutical and Bio-CDMO Product Features
Table 59：3P Biopharmaceuticals Biopharmaceutical and Bio-CDMO Revenue (Million USD) and Gross Margin (2021-2025)
Table 60：Global Biopharmaceutical and Bio-CDMO Market Size and Growth Forecast by Countries (2020 VS 2025 VS 2032) & (Million USD)
Table 61：Global Biopharmaceutical and Bio-CDMO Market Revenue by Countries (2020-2025) & (Million USD)
Table 62：Global Biopharmaceutical and Bio-CDMO Market Share by Countries (2020-2025)
Table 63：Global Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Countries (2026-2032) & (Million USD)
Table 64：Global Biopharmaceutical and Bio-CDMO Market Share Forecast by Countries (2026-2032)
Table 65：Global Biopharmaceutical and Bio-CDMO Market Revenue by Product Segment (2020-2025) & (Million USD)
Table 66：Global Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Product Segment (2026-2032) & (Million USD)
Table 67：Global Biopharmaceutical and Bio-CDMO Market Revenue by Product Application (2020-2025) & (Million USD)
Table 68：Global Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Product Application (2026-2032) & (Million USD)
Table 69：United States Biopharmaceutical and Bio-CDMO Market Revenue by Product Segment (2020-2025) & (Million USD)
Table 70：United States Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Product Segment (2026-2032) & (Million USD)
Table 71：United States Biopharmaceutical and Bio-CDMO Market Revenue by Product Application (2020-2025) & (Million USD)
Table 72：United States Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Product Application (2026-2032) & (Million USD)
Table 73：China Biopharmaceutical and Bio-CDMO Market Revenue by Product Segment (2020-2025) & (Million USD)
Table 74：China Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Product Segment (2026-2032) & (Million USD)
Table 75：China Biopharmaceutical and Bio-CDMO Market Revenue by Product Application (2020-2025) & (Million USD)
Table 76：China Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Product Application (2026-2032) & (Million USD)
Table 77：Germany Biopharmaceutical and Bio-CDMO Market Revenue by Product Segment (2020-2025) & (Million USD)
Table 78：Germany Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Product Segment (2026-2032) & (Million USD)
Table 79：Germany Biopharmaceutical and Bio-CDMO Market Revenue by Product Application (2020-2025) & (Million USD)
Table 80：Germany Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Product Application (2026-2032) & (Million USD)
Table 81：Japan Biopharmaceutical and Bio-CDMO Market Revenue by Product Segment (2020-2025) & (Million USD)
Table 82：Japan Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Product Segment (2026-2032) & (Million USD)
Table 83：Japan Biopharmaceutical and Bio-CDMO Market Revenue by Product Application (2020-2025) & (Million USD)
Table 84：Japan Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Product Application (2026-2032) & (Million USD)
Table 85：France Biopharmaceutical and Bio-CDMO Market Revenue by Product Segment (2020-2025) & (Million USD)
Table 86：France Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Product Segment (2026-2032) & (Million USD)
Table 87：France Biopharmaceutical and Bio-CDMO Market Revenue by Product Application (2020-2025) & (Million USD)
Table 88：France Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Product Application (2026-2032) & (Million USD)
Table 89：South Korea Biopharmaceutical and Bio-CDMO Market Revenue by Product Segment (2020-2025) & (Million USD)
Table 90：South Korea Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Product Segment (2026-2032) & (Million USD)
Table 91：South Korea Biopharmaceutical and Bio-CDMO Market Revenue by Product Application (2020-2025) & (Million USD)
Table 92：South Korea Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Product Application (2026-2032) & (Million USD)
Table 93：United Kingdom Biopharmaceutical and Bio-CDMO Market Revenue by Product Segment (2020-2025) & (Million USD)
Table 94：United Kingdom Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Product Segment (2026-2032) & (Million USD)
Table 95：United Kingdom Biopharmaceutical and Bio-CDMO Market Revenue by Product Application (2020-2025) & (Million USD)
Table 96：United Kingdom Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Product Application (2026-2032) & (Million USD)
Table 97：India Biopharmaceutical and Bio-CDMO Market Revenue by Product Segment (2020-2025) & (Million USD)
Table 98：India Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Product Segment (2026-2032) & (Million USD)
Table 99：India Biopharmaceutical and Bio-CDMO Market Revenue by Product Application (2020-2025) & (Million USD)
Table 100：India Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Product Application (2026-2032) & (Million USD)
Table 101：Italy Biopharmaceutical and Bio-CDMO Market Revenue by Product Segment (2020-2025) & (Million USD)
Table 102：Italy Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Product Segment (2026-2032) & (Million USD)
Table 103：Italy Biopharmaceutical and Bio-CDMO Market Revenue by Product Application (2020-2025) & (Million USD)
Table 104：Italy Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Product Application (2026-2032) & (Million USD)
Table 105：Brazil Biopharmaceutical and Bio-CDMO Market Revenue by Product Segment (2020-2025) & (Million USD)
Table 106：Brazil Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Product Segment (2026-2032) & (Million USD)
Table 107：Brazil Biopharmaceutical and Bio-CDMO Market Revenue by Product Application (2020-2025) & (Million USD)
Table 108：Brazil Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Product Application (2026-2032) & (Million USD)
Table 109：Mexico Biopharmaceutical and Bio-CDMO Market Revenue by Product Segment (2020-2025) & (Million USD)
Table 110：Mexico Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Product Segment (2026-2032) & (Million USD)
Table 111：Mexico Biopharmaceutical and Bio-CDMO Market Revenue by Product Application (2020-2025) & (Million USD)
Table 112：Mexico Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Product Application (2026-2032) & (Million USD)
Table 113：Indonesia Biopharmaceutical and Bio-CDMO Market Revenue by Product Segment (2020-2025) & (Million USD)
Table 114：Indonesia Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Product Segment (2026-2032) & (Million USD)
Table 115：Indonesia Biopharmaceutical and Bio-CDMO Market Revenue by Product Application (2020-2025) & (Million USD)
Table 116：Indonesia Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Product Application (2026-2032) & (Million USD)
Table 117：Vietnam Biopharmaceutical and Bio-CDMO Market Revenue by Product Segment (2020-2025) & (Million USD)
Table 118：Vietnam Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Product Segment (2026-2032) & (Million USD)
Table 119：Vietnam Biopharmaceutical and Bio-CDMO Market Revenue by Product Application (2020-2025) & (Million USD)
Table 120：Vietnam Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Product Application (2026-2032) & (Million USD)
Table 121：South Africa Biopharmaceutical and Bio-CDMO Market Revenue by Product Segment (2020-2025) & (Million USD)
Table 122：South Africa Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Product Segment (2026-2032) & (Million USD)
Table 123：South Africa Biopharmaceutical and Bio-CDMO Market Revenue by Product Application (2020-2025) & (Million USD)
Table 124：South Africa Biopharmaceutical and Bio-CDMO Market Revenue Forecast by Product Application (2026-2032) & (Million USD)
Table 125：Secondary Sources
Figure 1：Biopharmaceutical and Bio-CDMO Product Scope
Figure 2：Global Biopharmaceutical and Bio-CDMO Market Size and Growth Forecast Analysis (2020-2032) & (Million USD)
Figure 3：Global Biopharmaceutical and Bio-CDMO Product Segment Market Share (2025 & 2032)
Figure 4：Global Biopharmaceutical and Bio-CDMO Product Application Market Share (2025 & 2032)
Figure 5：Cell and Gene Therapies Product Scope
Figure 6：Antibodies Product Scope
Figure 7：Vaccines Product Scope
Figure 8：Others Product Scope
Figure 9：SMBs Product Scope
Figure 10：Large Companies Product Scope
Figure 11：Biopharmaceutical and Bio-CDMO Industrial Chain Framework
Figure 12：Global Biopharmaceutical and Bio-CDMO Market by Geographic Segmentation in 2025
Figure 13：Global Biopharmaceutical and Bio-CDMO Market Share by Countries (2020 VS 2025)
Figure 14：United States Biopharmaceutical and Bio-CDMO Market Size and Growth Forecast (2024 VS 2025 VS 2032) & (Million USD)
Figure 15：China Biopharmaceutical and Bio-CDMO Market Size and Growth Forecast (2024 VS 2025 VS 2032) & (Million USD)
Figure 16：Germany Biopharmaceutical and Bio-CDMO Market Size and Growth Forecast (2024 VS 2025 VS 2032) & (Million USD)
Figure 17：Japan Biopharmaceutical and Bio-CDMO Market Size and Growth Forecast (2024 VS 2025 VS 2032) & (Million USD)
Figure 18：France Biopharmaceutical and Bio-CDMO Market Size and Growth Forecast (2024 VS 2025 VS 2032) & (Million USD)
Figure 19：South Korea Biopharmaceutical and Bio-CDMO Market Size and Growth Forecast (2024 VS 2025 VS 2032) & (Million USD)
Figure 20：United Kingdom Biopharmaceutical and Bio-CDMO Market Size and Growth Forecast (2024 VS 2025 VS 2032) & (Million USD)
Figure 21：India Biopharmaceutical and Bio-CDMO Market Size and Growth Forecast (2024 VS 2025 VS 2032) & (Million USD)
Figure 22：Italy Biopharmaceutical and Bio-CDMO Market Size and Growth Forecast (2024 VS 2025 VS 2032) & (Million USD)
Figure 23：Brazil Biopharmaceutical and Bio-CDMO Market Size and Growth Forecast (2024 VS 2025 VS 2032) & (Million USD)
Figure 24：Mexico Biopharmaceutical and Bio-CDMO Market Size and Growth Forecast (2024 VS 2025 VS 2032) & (Million USD)
Figure 25：Indonesia Biopharmaceutical and Bio-CDMO Market Size and Growth Forecast (2024 VS 2025 VS 2032) & (Million USD)
Figure 26：Vietnam Biopharmaceutical and Bio-CDMO Market Size and Growth Forecast (2024 VS 2025 VS 2032) & (Million USD)
Figure 27：South Africa Biopharmaceutical and Bio-CDMO Market Size and Growth Forecast (2024 VS 2025 VS 2032) & (Million USD)
Figure 28：Research Methodology
Figure 29：Primary Sources
Figure 30：Data Cross Validation
Global Biopharmaceutical and Bio-CDMO Revenue and Market Share by Key Players
| Revenue (US$ Million) | 2020 | 2021 | 2022 | 2023 | 2024 |
| Lonza | XX | XX | XX | XX | XX |
| Catalent | XX | XX | XX | XX | XX |
| Samsung Biologics | XX | XX | XX | XX | XX |
| FUJIFILM Diosynth Biotechnologies | XX | XX | XX | XX | XX |
| Boehringer Ingelheim | XX | XX | XX | XX | XX |
| WuXi Biologics | XX | XX | XX | XX | XX |
| Recipharm | XX | XX | XX | XX | XX |
| Thermo Fisher Scientific | XX | XX | XX | XX | XX |
| AGC Biologics | XX | XX | XX | XX | XX |
| Rentschler Biopharma | XX | XX | XX | XX | XX |
| KBI Biopharma | XX | XX | XX | XX | XX |
| Siegfried | XX | XX | XX | XX | XX |
| Aenova Group | XX | XX | XX | XX | XX |
| GenScript | XX | XX | XX | XX | XX |
| ProBioGen | XX | XX | XX | XX | XX |
| Northway Biotech | XX | XX | XX | XX | XX |
| 3P Biopharmaceuticals | XX | XX | XX | XX | XX |
| Other Companies | XX | XX | XX | XX | XX |
| Total | XX | XX | XX | XX | XX |
English
Related Reports 
